がん全体にわたるApCAF:空間的ニッチと治療的洞察
Wenlong Li1, Gideon Nsubuga1, Giulia Biffi1
1Cancer Research UK Cambridge Institute, Li Ka Shing Centre, University of Cambridge, Cambridge, UK.
Trends in cancer
|December 31, 2025
まとめ
研究者らは、オステオポンチンを発現する抗原提示がん関連線維芽細胞(apCAF)の2つの異なる集団を特定した。これらのapCAFサブタイプは、腫瘍内の異なる場所に存在し、がんにおける多様な役割を示唆している。
科学分野:
- 腫瘍学
- 免疫学
- 細胞生物学
背景:
- 抗原提示がん関連線維芽細胞(apCAF)は、腫瘍進行におけるその役割のためにますます認識されている。
- apCAFの特定のサブタイプと治療上の可能性はよく理解されていない。
- オステオポンチンは、様々な癌に関与するタンパク質である。
研究 の 目的:
- 様々な悪性腫瘍における抗原提示がん関連線維芽細胞(apCAF)の異質性の調査。
- 起源、場所、および分子マーカーに基づいてapCAFの異なる集団の特性評価。
- 同定されたapCAFサブタイプの潜在的な治療的含意の探求。
主な方法:
- 様々な癌種の腫瘍サンプルの分析。
- 線維芽細胞集団の同定と特性評価のための免疫組織化学および単一細胞RNAシーケンシング。
- apCAFにおけるオステオポンチン発現の評価。
- 癌細胞やリンパ球などの腫瘍微小環境の特徴とapCAFの位置との相関。
主要な成果:
- 複数の癌種にわたる2つの異なるオステオポンチン発現apCAF集団の同定。
- 癌細胞の近くに位置する中皮細胞様(M-)apCAFの特性評価。
- リンパ球豊富なニッチに関連する線維芽細胞様(F-)apCAFの特性評価。
- これらのapCAFサブタイプが腫瘍微小環境内の起源と空間分布において異なることの実証。
結論:
- 腫瘍微小環境内にオステオポンチン発現apCAFの2つの異なるサブタイプが存在する。
- M-apCAFおよびF-apCAFは、特殊化された機能を示唆する独自の局在パターンを示す。
- これらのapCAFサブタイプの理解は、標的化された癌治療の開発にとって重要である。
関連する概念動画
Targeted Cancer Therapies
8.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
8.6K
Cancer Therapies
9.8K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
9.8K
Treatment Resistant Cancers
3.7K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.7K
Combination Therapies and Personalized Medicine
5.8K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.8K
Tumor Immunotherapy
1.7K
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
1.7K
The Tumor Microenvironment
7.6K
Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...
7.6K


